Afatinib
CAS: 850140-72-6
Ref. TM-T21312
| 5mg | 35.00 € | ||
| 10mg | 51.00 € | ||
| 25mg | 84.00 € | ||
| 50mg | 113.00 € | ||
| 100mg | 142.00 € | ||
| 200mg | 174.00 € | ||
| 500mg | 294.00 € | ||
| 1mL*10mM (DMSO) | 53.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
Product Information
Name:
Afatinib
Synonyms:
- BIBW 2992
- Afatinib free base
- (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
- (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- (E)-N-(7-((S)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide
- (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-dime
- 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-
- 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-
- Bibw 2992
- Bibw2992
- See more synonyms
- Gilotrif
- Giotrif
- Tovok
Description:
Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
485.94
Formula:
C24H25ClFN5O3
Purity:
97.56% - 99.9%
Color/Form:
Off-White Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T21312 Afatinib
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
